S. Goranov

发表

High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients – final analysis of a randomized, multicenter, phase III trial

T. Lion, Thomas Grubinger, N. Tzvetkov, 2012, Haematologica.

High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 “ISTAHIT” study

T. Lion, H. Ulmer, N. Tzvetkov, 2010, Haematologica.

Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations.

S. Goranov, P. Pavlov, V. Goranova-Marinova, 2007, Haematologica.

CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph + /BCR-ABL + CML Patients in Chronic Phase.

T. Lion, H. Ulmer, N. Tzvetkov, 2008 .

Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study

R. Foà, G. Juliusson, M. Montillo, 2008 .

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

A. Glasmacher, R. Hájek, H. Avet-Loiseau, 2012, Haematologica.

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial

G. Juliusson, M. Montillo, T. Lissitchkov, 2012, British journal of haematology.

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

L. Tremmel, G. Juliusson, M. Montillo, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple Myeloma with Advanced Bone Disease and Low Tumor Burden - Different Clinical Presentation but Similar Outcome after Bortezomib-Based Therapy and Radiotherapy.

T. Deneva, S. Goranov, V. Goranova-Marinova, 2017, Acta clinica Croatica.

High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival – Final Results of the CELSG Phase III CML11 “ISTAHIT” Trial

T. Lion, Thomas Grubinger, G. Gastl, 2010 .

A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).

A. Jakubowiak, D. Siegel, P. Moreau, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palliative radiotherapy in patients with multiple myeloma.

S. Goranov, M. Yaneva, V. Goranova-Marinova, 2006, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

L. Tremmel, G. Juliusson, M. Montillo, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial

G. Juliusson, M. Montillo, T. Lissitchkov, 2012, British journal of haematology.